This site is intended for healthcare professionals registered in Ireland.

References

  1. TRIXEO AEROSPHERE 5 micrograms/7.2 micrograms/160 micrograms pressurized inhalation, suspension. Summary of Product Characteristics. Available at www.medicines.ie
  2. Rabe KF et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. doi: 10.1056/NEJMoa1916046.
  3. AstraZeneca. Data on File. Veeva Approval ID: REF-54777. May 2019.
  4. Martinez FJ et al. Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial. Am J Respir Crit Care Med 2020;201:A5073.
  5. Rabe KF et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very severe COPD. N Engl J Med. 2020;383:35–48. (Supplementary appendix) doi: 10.1056/NEJMoa1916046.
  6. Ferguson GT et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi: 10.1016/S2213-2600(18)30327-8
  7. Van den Berge M et al. Presented at the CHEST 2020 Virtual Congress, October 2020. P1456.
  8. Israel S et al. Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci. 2020;153:105472. doi: 10.1016/j.ejps.2020.105472.
  9. Vehring R et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015–15023. doi: 10.1021/la302281n
  10. Rabe KF et al. Late breaking abstract—COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS. Eur Respir J. 2020;56:5230. doi: 10.1183/13993003. congress-2020.5230.

  11. Taylor G et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111: 450–457. doi: 10.1016/j.ejps.2017.10.026.

  12. Ferguson GT et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with

    co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease

    (KRONOS): a double-blind, parallel-group,  multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. (Supplementary appendix).